R. Douglas Bruce, MD, MA, MS

A. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with known atherosclerotic cardiovascular disease (ASCVD)

B. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with and without known ASCVD

C. GLP-1RAs decrease heart failure events among those with heart failure with preserved ejection fraction and with obesity

D. GLP-1RAs reduce the severity of substance use disorders

E. All of the above